Multicenter, Observational, Descriptive Study of the Diagnosis, Course and Treatment of Patients With SLE in Routine Practice in Kazakhstan: a Registry Study With Retrospective and Prospective Components.

Launched by ASTRAZENECA · Mar 26, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how systemic lupus erythematosus (SLE) affects patients in Kazakhstan. SLE is a chronic illness that can impact various parts of the body, and this study aims to gather information about how it is diagnosed, how it progresses, and what treatments are commonly used in everyday medical practice. The researchers will collect data both from past records (retrospective) and from new patients who join the study (prospective) to get a comprehensive view of SLE in the region.

To be eligible for this study, participants need to be adults aged 18 and older who have been officially diagnosed with SLE. They will need to provide written consent to take part in the study. However, people with certain cognitive challenges that make it hard to understand the study or those currently involved in other clinical trials cannot participate. If you join the study, you can expect to share information about your health and treatment, which will help improve understanding and care for others with SLE in Kazakhstan.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Men and women aged 18 years and older with a verified diagnosis of SLE
• • Patient signed and dated written informed consent form (ICF) by ICH GCP and local legislation prior to inclusion in the study for the prospective observational group.
• • Exclusion Criteria
• • Absence of a signed consent form (ICF) in patients
• • Cognitive impairments that hinder understanding the study objectives and completing questionnaires
• • Participation in any randomized controlled clinical trial within 3 months prior to inclusion or during participation in this study.